论文部分内容阅读
目的:对注射用重组人尿激酶原始疗急性心肌梗死的疗效进行分析。方法:选取我院2015年7月~2016年7月40例急性心肌梗死患者作为本次研究对象,随机将其分为观察组与对照组,每组20例,观察组患者采用重组人尿激酶原(Pro-UK)溶栓治疗,对照组采用尿激酶(UK)溶栓治疗,对治疗结果进行分析比较。结果:观察组患者溶栓后再通率明显高于对照组(P<0.05);对溶栓后两组患者的并发症进行比较分析,两组患者中均未出现死亡,再次心肌梗死和心力衰竭相较而言,两组患者的差异较小,无统计学意义,梗死后心绞痛和出血发生率差异较大(P<0.05),具有统计学意义。结论:注射用重组人尿激酶原治疗急性心肌梗死可取得较好的效果,溶栓治疗急性心肌梗死的成功率较高,且安全性更高,对于急性心肌梗死的早期急性治疗十分有利,具有临床推广价值。
OBJECTIVE: To analyze the efficacy of recombinant human urokinase for the treatment of acute myocardial infarction. Methods: Forty patients with acute myocardial infarction from July 2015 to July 2016 in our hospital were selected as the study subjects. They were randomly divided into observation group and control group, 20 cases in each group. The patients in observation group were treated with recombinant human urokinase (Pro-UK) thrombolytic therapy, the control group with urokinase (UK) thrombolytic therapy, the treatment results were analyzed and compared. Results: The recanalization rate after thrombolysis in observation group was significantly higher than that in control group (P <0.05). Comparisons were made between the two groups after thrombolysis. There were no deaths in both groups, again myocardial infarction and cardiac function Compared with the failure, the difference between the two groups was small, with no statistical significance, the incidence of post-infarction angina pectoris and bleeding was significantly different (P <0.05), with statistical significance. Conclusion: Injection of recombinant human prourokinase for acute myocardial infarction can achieve better results, thrombolytic therapy of acute myocardial infarction with a higher success rate and higher safety, acute acute myocardial infarction in the early acute treatment is very beneficial, with Clinical promotion value.